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Abstract 
Malignant hemorrhagic ascites may complicate the terminal evolution of digestive cancers 
with peritoneal carcinomatosis. It has a bad influence on prognosis and may severely impair 
patients’ quality of life. Palliative laparoscopic hyperthermic intraperitoneal chemotherapy 
(HIPEC) has been proposed to treat debilitating malignant ascites. Two cases of peritoneal 
carcinomatosis causing hemorrhagic ascites and severe anemia that needed iterative blood 
transfusions are reported. These patients were treated by laparoscopic HIPEC (mitomycin C 
and cisplatin with an inflow temperature of 43°C), resulting in cessation of peritoneal 
bleeding. No postoperative complication or relapse of ascites occurred during the following 
months. No more blood transfusion was needed. Laparoscopic HIPEC might be an effective 
and safe therapeutic option to consider in patients with malignant hemorrhagic ascites. 
 
Introduction 
Malignant ascites may occur in the evolution of digestive or gynecologic cancers 
when disseminated to the intra-abdominal cavity [1, 2]. There are several factors 
participating to its constitution [1]. Disseminated intra-abdominal tumor induces  
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peritoneal neovascularization and increases microvascular permeability and 
production of peritoneal fluid. Besides, intraperitoneal fluid accumulation is also 
related to intra-abdominal and diaphragmatic lymph vessel obstruction due to tumor 
invasion [1]. Hemoperitoneum is a rare but poor prognosis complication of peritoneal 
carcinomatosis. It can be due to vascular extension of peritoneal carcinomatosis or 
bleeding from the primary tumor. Patients’ quality of life is often severely impaired due 
to symptoms including chronic anemia, and even worsened by repeated paracentesis 
and blood transfusions. 
Iterative paracentesis, diuretics and albumin perfusion are used to treat cirrhotic 
ascites and might be useful to treat malignant ascites at its beginning, but lose 
effectiveness over time because of different physiopathology. As peritoneal 
dissemination is a major poor prognosis factor in patients with intra-abdominal 
malignancy, it represents a classical contraindication for aggressive therapeutic 
strategies such as surgical resection. Palliative laparoscopic hyperthermic 
intraperitoneal chemotherapy (HIPEC) has been proposed to treat debilitating 
malignant ascites [1, 3–7]. The goal of this procedure is palliative symptom relief with 
reduced invasiveness and morbidity. To our knowledge, no treatment has been 
reported to show effectiveness in carcinomatosis-associated hemoperitoneum, and 
patients are usually treated with iterative paracentesis, repeated blood transfusions 
and eventual palliative systemic chemotherapy. Two patients with peritoneal 
carcinomatosis causing malignant ascites and peritoneal bleeding requiring iterative 
blood transfusion treated by laparoscopic HIPEC are reported. 
Case 1 
A 48-year-old Caucasian man was referred for management of ascites. Endoscopic examination 
of the upper gastrointestinal tract showed a thickened and stiff appearance of the cardial region. 
Histological examination of gastric biopsies showed evidence of undifferentiated adenocarcinoma 
with independent cells. Abdominal computed tomography (CT) scan was suggestive of gastric linitis 
with synchronous peritoneal carcinomatosis. The patient was treated by chemotherapy in the 
AVAGAST randomized study (6 cycles of capecitabine and cisplatin +/– bevacizumab, then 14 cycles 
of capecitabine +/– bevacizumab). After 15 months of chemotherapy the disease was uncontrolled, 
as ascites relapsed more often and became hemorrhagic. A second-line chemotherapy using 
5-fluorouracil and oxaliplatin did not have an effect on hemorrhagic ascites. Anemia was severe 
(mean hemoglobin 5.2–8.7 g/dl) and needed iterative blood transfusions (1 unit of blood every 
7 days), erythropoietin and iron intravenous injection. No active bleeding could be observed on CT 
scan. As blood transfusions were more and more frequent, an explorative laparoscopy followed by 
HIPEC was proposed after discussion in multidisciplinary care team meeting. 
Explorative laparoscopy confirmed hemorrhagic ascites in which hemoglobin was measured at 
0.6 g/dl. The primary tumor was ill-bounded and completely sheathed the submesocolic region, and 
particularly the left lobe of the liver. The epiploon was impaired by carcinomatosis, but the small 
intestine and pelvis were not involved. The HIPEC procedure consisted in intraperitoneal perfusion of 
mitomycin C (75 mg) and cisplatin (250 mg) during 30 min with an inflow temperature of 43°C under 
laparoscopy. Operative time was 120 min. The postoperative course was unremarkable. 
During the following months the ascites did not relapse and no carcinomatous nodule was 
palpable. Hemoglobin became stable (11.2 g/dl) and no more transfusion support was needed. Fig. 1 
shows the evolution of hemoglobin over time. A simple surveillance was then decided. Five months 
after laparoscopy, the ascites relapsed, and scanography showed progression of the disease. The 
patient then received everolimus or placebo in the GRANIT study, but died 2 months later, 7 months 
after surgery and 25 months after diagnosis.  
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Case 2 
A 78-year-old woman presented with ascites. CT scan showed peritoneal carcinomatosis with 
multiple abdominal and pelvic nodes. A diagnostic laparoscopy was performed and found a pelvic 
infiltrative tumor with diffuse infracentimetric peritoneal carcinomatosis nodes. Pathological 
examination of the preoperative samples showed a poorly differentiated adenocarcinoma. No primary 
tumor could be clearly identified, although ovarian origin was strongly suspected. Despite systemic 
chemotherapy with cisplatin- (8 cycles) and paclitaxel-based regimen (2 cycles), the patient suffered 
from abundant bloody ascites with severe anemia (mean hemoglobin 6.1–9.5 g/dl) that required 
iterative paracenteses (one paracentesis every 4 days) and transfusion support. 
After discussion in multidisciplinary care team meeting, laparoscopic HIPEC was proposed. 
Preoperative exploration confirmed the ill-bounded pelvic bulk, with retro- and subperitoneal 
development. Peritoneal carcinomatosis consisted in a diffuse involvement of all quadrants. The 
procedure consisted in intraperitoneal perfusion of mitomycin C (75 mg) and cisplatin (184 mg) 
for 20 min with an inflow temperature of 43°C. Operative time was 120 min. No postoperative 
complication occurred. This therapeutic procedure resulted in regression of ascites and complete 
resolution of hemoperitoneum, leading to cessation of blood transfusions and improvement of quality 
of life. 
Three months later, as the patient complained of asthenia and weight loss. A CT scan was 
performed and showed resurgence of ascites and progression of the abdominal lesions. Best 
supportive care was decided, and the patient died 3 weeks later. 
Discussion 
Malignant ascites may complicate digestive or gynecologic cancers in their terminal 
phase, especially ovarian or gastric cancer. The prognosis is poor as median survival 
rarely exceeds 6 months [1]. In their retrospective analysis of 209 patients with 
malignant ascites, Ayantunde and Parsons [2] reported a median survival time of 
5.7 months after diagnosis of ascites. 
Malignant ascites may be complicated by hemorrhage, leading to chronic anemia. 
This can be due to vascular extension of peritoneal carcinomatosis or bleeding from the 
primary tumor. Hemorrhagic malignant ascites might be an even poorer prognostic 
factor due to anemia and repeated blood transfusions. No treatment has shown its 
effectiveness on peritoneal bleeding associated to malignant ascites. As malignant 
ascites is a poor prognostic factor, the aim of therapy is palliation and improvement of 
quality of life [3]. Therapeutics used in cirrhotic ascites are usually ineffective since the 
physiopathology is different. Iterative paracentesis and intravenous chemotherapy may 
be initially effective, but classically lose their effectiveness over time. 
Use of palliative laparoscopic HIPEC has been proposed to treat debilitating 
malignant ascites [1, 4–8]. By destroying the peritoneal carcinomatosis, HIPEC may 
induce hemostasis and progressive fibrosis of the peritoneum, preventing ascites and 
bleeding [4, 5]. However, HIPEC is linked to important morbidity and mortality, mostly 
determined by the extent of cytoreduction and peritoneal resection, the number of 
digestive anastomoses, the dose of chemotherapy and the operative time [9]. In 
patients with malignant ascites and eventually related hemoperitoneum, the 
therapeutic goal is not increased survival but palliative symptom relief. In this way, no 
extended resection is required that might result in a relative decrease of the morbidity 
impact related to HIPEC. The laparoscopic approach has been considered in the last 
decade in an attempt to reduce the invasiveness of the procedure in patients  
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undergoing HIPEC with a palliative intent [5, 9]. Indeed, laparoscopic HIPEC may 
integrate the benefits of a definitive palliation of ascites with a minimal invasion, 
leading to fewer postoperative complications. Retrospective studies related complete 
clinical regression of ascites in most patients, resulting in symptom relief, and 
significant improvement in quality of life [4–8]. In the larger studies, Valle et al. [7] 
reported a definitive regression of ascites in 94% of 52 patients. 
Although laparoscopic HIPEC has been evaluated in patients with malignant ascites, 
we have presented here the originality of its efficacy in malignant hemoperitoneum 
[4, 7]. We have reported two cases of peritoneal carcinomatosis causing peritoneal 
bleeding requiring iterative blood transfusion, treated by laparoscopic HIPEC, resulting 
in the reduction of debilitating ascites and cessation of peritoneal bleeding without 
postoperative complication. This laparoscopic procedure could be considered as a 
palliative success as far as it improved quality of life and reduced symptoms, especially 
anemia. Ba et al. [8] reported that 2 of their 16 patients presented bloody ascites that 
turned clear after laparoscopic HIPEC, but there is no information about the severity of 
peritoneal bleeding in these patients. However, this supports that laparoscopic HIPEC 
might be effective to dry up carcinomatosis-associated peritoneal bleeding. Although 
there are not enough reported cases of laparoscopic HIPEC to treat malignant bleeding 
ascites, we may consider it as a therapeutic option. 
Recent studies reported the potential benefit of using new targeted agents by 
intraperitoneal route in malignant ascites. Heiss et al. [10] demonstrated clinically 
relevant benefits of catumaxomab in patients with recurrent malignant ascites due to 
carcinomas of different origin, with frequent but acceptable chemo-induced toxicity. 
Additionally, bevacizumab is currently under evaluation in clinical studies to treat and 
prevent malignant ascites [11]. Combination of laparoscopic HIPEC with these targeted 
drugs might be an option to consider, and its efficacy and toxicity should be evaluated.  
In conclusion, laparoscopic HIPEC might be an interesting therapeutic option in 
selected patients with debilitating malignant ascites associated with hemoperitoneum. 
This technique appears to be interesting because of improvement of quality of life with 
a minimally invasive approach. 
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Fig. 1. Evolution of hemoglobin and transfusion support in case 1. After laparoscopic HIPEC, 
hemoglobin became stable and no more transfusions were needed. 
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